Market OverviewThe global Newborn Screening Market is valued at USD 3.44 Billion in 2024 and is projected to reach a value of ...

Relief’s 2024 Annual Report, which includes pipeline and portfolio updates, corporate governance and compensation disclosures, and financial statements, is available on the Company’s website.

Global Newborn Screening Market is projected to grow at a CAGR of ~6–8% from 2022 to 2027. This is likely to be driven by an ...

BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could ...

US biotech BioMarin Pharmaceutical (Nasdaq: BMRN) yesterday revealed that the Phase III PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a ...

Based on the late-stage data, BioMarin plans to submit a regulatory filing for expanding the label of its PKU drug Palynziq in adolescents before this year's end.

San Rafael, California Thursday, April 3, 2025, 18:00 Hrs [IST] ...

The WHO report, which was based on population data, found that long-term consumption of sweeteners found in 'diet' soft ...

BioMarin has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its primary ...

SAN RAFAEL, CA, USA I April 2, 2025 I BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ ® (pegvaliase-pqpz) met its primary efficacy ...

Untreated phenylketonuria can lead to brain damage, intellectual disabilities, behavioral symptoms or seizures. The primary ...